| Tamburini, Emiliano |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 31 | Europe | Abemaciclib, Aromatase Inhibitors | University of Milano Bicocca | Advanced Breast Cancer | 12/23 | 12/23 | | |
ECLYPse, NCT06640166: Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. |
|
|
| Recruiting | 2 | 25 | Europe | encorafenib + cetuximab + FOLFIRI, encorafenib, cetuximab, FOLFIRI | Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Pierre Fabre Pharma GmbH | Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor, Colorectal Adenocarcinoma, Colorectal Cancer (CRC), Colorectal Cancer, Colon Cancer, Colon Adenocarcinoma, Colon Carcinoma, Colon Neoplasm | 12/25 | 06/26 | | |
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC |
|
|
| Recruiting | 2 | 16 | Europe | Cetuximab, Encorafenib | Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories | Colorectal Cancer | 08/26 | 04/27 | | |
CombiCoR-Vax, NCT06522919: Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 36 | Europe | Autologous Dendritic Cell (DC) Vaccine | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer | 04/26 | 09/26 | | |
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy |
|
|
| Recruiting | 2 | 173 | Europe | Cetuximab, Erbitux, Avelumab, Bavencio | University of Campania "Luigi Vanvitelli" | Metastatic Colorectal Cancer | 07/25 | 07/25 | | |
| Active, not recruiting | 2 | 219 | Europe | Cetuximab, Erbitux, FOLFIRI, FOLFOX regimen, FOLFOX, Irinotecan | University of Campania "Luigi Vanvitelli" | Metastatic Colorectal Adenocarcinoma | 08/25 | 06/26 | | |
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients |
|
|
| Recruiting | 2 | 477 | Europe | 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib | Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc. | Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer | 10/25 | 12/27 | | |
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer |
|
|
| Recruiting | N/A | 150 | Europe | | University of Milano Bicocca | Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer | 01/24 | 01/24 | | |
NCT04416672: Validation of the Italian Version of the PRO-CTCAE |
|
|
| Recruiting | N/A | 3675 | Europe | PRO-CTCAE items | National Cancer Institute, Naples | Malignant Neoplasms | 07/24 | 07/24 | | |
